May 1999
international
abstracts:
home
transplantation
|
|
|
| |
May 1999 international |
|
alzheimer's issues: february 2003 november 2002 august 2002 may 2002 february 2002 november 2001 august 2001 may 2001 february 2001 november 2000 august 2000 june 2000 march 2000 november 1999 may 1999 february 1999 september 1998 june 1998 march 1998 december 1997 |
IN THIS ISSUENON-GENETIC RISK FACTORS FOR DEMENTIA
NEW GENETIC FACTORS IN ALZHEIMER'S DISEASE
DEMENTIA IN PARKINSON'S DISEASE
|
| EDITORIAL FOREWORD |
NON-GENETIC
RISK FACTORS FOR DEMENTIA
There is always a strong interest in discovering risk factors for dementia,
since this knowledge could lead to etiological hypothesis and preventive
approaches in aging populations. The control of systolic hypertension
is a good example of how epidemiology of dementia has led to preventive
therapy (Forette et al). Fortunately, general anesthesia was not found
to be a risk factor for age-associated cognitive decline (Dijkstra et
al), although post-operative delirium is well described (Ritchie
et al) and may be amenable to treatment by donepezil (Wengel
et al). Head injuries are not a specific factor for Alzheimer's
disease (Launer et al). |
| FRANÇOISE FORETTE, MARIE-LAURE SEUX, JAN A. STAESSEN, LUTGARDE THIJS, ET AL, PARIS, FRANCE, LEUVEN, BELGIUM, ROTTERDAM, NETHERLANDS, BUCHAREST, ROMANIA, VARIOUS OTHER CENTRES |
| JEANETTE B. DIJKSTRA, PHD, MARTIN P.J. VAN BOXTEL, MD, PHD, PETER J. HOUX, PHD, JELLEMER JOLLES, PHD, MAASTRICHT, THE NETHERLANDS |
| KAREN RITCHIE, CATHERINE POLGE, GUILHEM DE ROQUEFEUIL, MICHEL DJAKOVIC, BERNARD LEDESERT, MONTPELLIER, FRANCE |
| STEVEN P. WENGEL, MD, WILLIAM H. ROCCAFORTE, MD, WILLIAM J. BURKE, MD, OMAHA, NEBRASKA |
| L.J. LAUNER, PHD, K. ANDERSEN, MD, M.E. DEWEY, PHD, L. LETENNEUR, PHD, ET AL, ROTTERDAM, THE NETHERLANDS, BORDEAUX, FRANCE, FLORENCE, ITALY, PAMPLONA, SPAIN |
| EDITORIAL COMMENT |
This complex field has recently been reviewed by Levy-Lahad et
al, but already new findings suggest a role for the DLST gene on chromosome
14 (Sheu et al), and for a new gene on chromosome 12 (Zubenko et
al). The latter evidence adds to the controversy regarding the importance
of mutations on chromosome 12, confirmed (Rogaeva et al, FAX back
section) and denied (Wu et al, FAX back section) by excellent laboratories. |
| EPHRAT LEVY-LAHAD, MD, DEBBY TSUANG, MD, MSC, THOMAS D. BIRD, MD, SEATTLE, WA |
| KWAN-FU REX SHEU, PHD, ABRAHAM M. BROWN, PHD, VAHRAM HAROUTUNIAN, PHD, BRUCE S. KRISTAL, PHD, ET AL, MANHASSET, NY, CLEVELAND, OH, STOCKHOLM, SWEDEN |
| GEORGE S. ZUBENKO,
MD, PHD, HUGH B. HUGHES, III, MS, J. SCOTT STIFFLER, BS, PITTSBURGH, PA |
| EDITORIAL COMMENT |
There is an increased interest in dementia associated with Parkinson's
disease (PD). Detection of dementia in persons with PD is facilitated by
the CAMCOG (Hobson and Meara). Longitudinal studies have confirmed a relative
risk of 1.7 for developing dementia in persons with PD (Marder et al),
and first degree relatives of demented PD patients are at higher risk of
developing Alzheimer's disease (Marder et al, FAX back section).
The dementia associated with PD is often confounded with drug-induced psychosis,
which was found to be responsive to low-dose clozapine (The PSG). |
| PETER HOBSON, JOLYON MEARA, DENBIGHSHIRE, UK |
| KAREN MARDER, MD, MPH, MING-XIN TANG, PHD, LUCIEN COTE, MD, YAAKOV STERN, PHD, RICHARD MAYEUX, MD, MSE, NEW YORK, NY |
| THE PARKINSON STUDY GROUP, PAWTUCKET, RI |
